Ken Kikuchi

1.0k total citations
36 papers, 736 citations indexed

About

Ken Kikuchi is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Ken Kikuchi has authored 36 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Ken Kikuchi's work include Sarcoma Diagnosis and Treatment (17 papers), CAR-T cell therapy research (5 papers) and Neuroblastoma Research and Treatments (5 papers). Ken Kikuchi is often cited by papers focused on Sarcoma Diagnosis and Treatment (17 papers), CAR-T cell therapy research (5 papers) and Neuroblastoma Research and Treatments (5 papers). Ken Kikuchi collaborates with scholars based in Japan, United States and Switzerland. Ken Kikuchi's co-authors include Hajime Hosoi, Tomoko Iehara, Shigeki Yagyu, Mitsuru Miyachi, Kunihiko Tsuchiya, Yoshiki Katsumi, Charles Keller, Hideki Yoshida, Shinichi Tamura and Takahiro Gotoh and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Scientific Reports.

In The Last Decade

Ken Kikuchi

35 papers receiving 723 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ken Kikuchi Japan 16 472 289 270 244 95 36 736
Domenico Trombetta Italy 12 358 0.8× 209 0.7× 247 0.9× 266 1.1× 54 0.6× 36 731
Joanna Selfe United Kingdom 15 510 1.1× 266 0.9× 175 0.6× 200 0.8× 45 0.5× 26 819
Savita Sankar United States 10 532 1.1× 426 1.5× 120 0.4× 134 0.5× 55 0.6× 12 833
Swethajit Biswas United Kingdom 12 424 0.9× 200 0.7× 249 0.9× 209 0.9× 32 0.3× 22 690
Eva Pros Spain 14 372 0.8× 160 0.6× 84 0.3× 159 0.7× 133 1.4× 19 619
Anna Serur United States 9 430 0.9× 110 0.4× 203 0.8× 221 0.9× 80 0.8× 15 646
Victoria A. Robb United States 12 518 1.1× 181 0.6× 85 0.3× 132 0.5× 78 0.8× 14 872
Rebekka Unland Germany 8 351 0.7× 221 0.8× 121 0.4× 116 0.5× 26 0.3× 9 510
Juan‐Han Yu China 17 409 0.9× 200 0.7× 124 0.5× 226 0.9× 31 0.3× 62 775
Stephanie Plehm Germany 6 328 0.7× 210 0.7× 114 0.4× 105 0.4× 25 0.3× 7 488

Countries citing papers authored by Ken Kikuchi

Since Specialization
Citations

This map shows the geographic impact of Ken Kikuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Kikuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Kikuchi more than expected).

Fields of papers citing papers by Ken Kikuchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Kikuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Kikuchi. The network helps show where Ken Kikuchi may publish in the future.

Co-authorship network of co-authors of Ken Kikuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Kikuchi. A scholar is included among the top collaborators of Ken Kikuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Kikuchi. Ken Kikuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iehara, Tomoko, Ken Kikuchi, Shigeki Yagyu, et al.. (2022). The histone deacetylase inhibitor OBP‐801 has in vitro/in vivo anti‐neuroblastoma activity. Pediatrics International. 64(1). e15159–e15159. 5 indexed citations
2.
Andrieux, Geoffroy, Michaela Schneider, Manching Ku, et al.. (2021). Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma. Life Science Alliance. 4(9). e202001002–e202001002. 9 indexed citations
3.
Miyachi, Mitsuru, Shigeki Yagyu, Ken Kikuchi, et al.. (2021). Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma. Scientific Reports. 11(1). 18802–18802. 10 indexed citations
4.
Yagyu, Shigeki, Kayoko Nakamura, Ken Kikuchi, et al.. (2021). Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Molecular Therapy — Oncolytics. 20. 646–658. 24 indexed citations
5.
Katsumi, Yoshiki, Tomoko Iehara, Hideki Yoshida, et al.. (2020). The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA. Molecular Cancer Therapeutics. 19(10). 1992–2000. 5 indexed citations
6.
Miyachi, Mitsuru, Shigeki Yagyu, Ken Kikuchi, et al.. (2020). Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells. Cancer Cell International. 20(1). 192–192. 7 indexed citations
7.
Iehara, Tomoko, Shigeki Yagyu, Takahiro Gotoh, et al.. (2019). A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients. Japanese Journal of Clinical Oncology. 49(8). 743–748. 11 indexed citations
8.
Kikuchi, Ken, Kunihiko Tsuchiya, Yoshiki Katsumi, et al.. (2016). MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells. Oncology Reports. 37(1). 98–104. 15 indexed citations
9.
Miyachi, Mitsuru, Kunihiko Tsuchiya, Yoshihiro Nitta, et al.. (2015). Diagnostic and prognostic role of circulating miR-206 in rhabdomyosarcoma patients.. Journal of Clinical Oncology. 33(15_suppl). 10038–10038. 1 indexed citations
10.
Kikuchi, Ken, et al.. (2013). Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. Oncogene. 33(15). 1877–1889. 24 indexed citations
11.
Yoshida, Hideki, Mitsuru Miyachi, Shigeki Yagyu, et al.. (2013). PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells. Oncogene. 33(49). 5601–5608. 22 indexed citations
12.
Kikuchi, Ken, Anuradha Soundararajan, Lee Ann Zarzabal, et al.. (2012). Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 32(3). 286–295. 28 indexed citations
13.
Kikuchi, Ken, Brian P. Rubin, & Charles Keller. (2011). Developmental Origins of Fusion-Negative Rhabdomyosarcomas. Current topics in developmental biology. 96. 33–56. 19 indexed citations
14.
Yagyu, Shigeki, Tomoko Iehara, Takahiro Gotoh, et al.. (2011). Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: A novel diagnostic tool for therapy stratification of neuroblastoma. Cancer Letters. 309(2). 185–189. 23 indexed citations
15.
Miyachi, Mitsuru, Kunihiko Tsuchiya, Hideki Yoshida, et al.. (2010). Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 400(1). 89–93. 113 indexed citations
16.
Miyachi, Mitsuru, Naoki Kakazu, Shigeki Yagyu, et al.. (2009). Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells. Clinical Cancer Research. 15(12). 4077–4084. 75 indexed citations
17.
Yagyu, Shigeki, Takahiro Gotoh, Tomoko Iehara, et al.. (2008). Circulating Methylated- DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma. Clinical Cancer Research. 14(21). 7011–7019. 34 indexed citations
18.
Katsumi, Yoshiki, Yasumichi Kuwahara, Shinichi Tamura, et al.. (2008). Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity. Clinical Cancer Research. 14(4). 1192–1199. 15 indexed citations
19.
Kikuchi, Ken, Kunihiko Tsuchiya, Takahiro Gotoh, et al.. (2007). Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 365(3). 568–574. 81 indexed citations
20.
Matsuhisa, Akio, Akihiro Tanaka, Ken Kikuchi, et al.. (1997). Nonpeptide Arginine Vasopressin Antagonists for Both V1A and V2 Receptors: Synthesis and Pharmacological Properties of 2-Phenyl-4'-((2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)benzanilide Derivatives.. Chemical and Pharmaceutical Bulletin. 45(11). 1870–1874. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Domenico Trombetta Breakdown of academic impact, for papers by Joanna Selfe Breakdown of academic impact, for papers by Savita Sankar Breakdown of academic impact, for papers by Swethajit Biswas Breakdown of academic impact, for papers by Eva Pros Breakdown of academic impact, for papers by Anna Serur Breakdown of academic impact, for papers by Victoria A. Robb Breakdown of academic impact, for papers by Rebekka Unland Breakdown of academic impact, for papers by Juan‐Han Yu Breakdown of academic impact, for papers by Stephanie Plehm
Rankless by CCL
2026